Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells

Sheng Tai; Lingfan Xu; Ming Xu; Ligang Zhang; Yangyang Zhang; Kaipin Zhang; Li Zhang; Chaozhao Liang

doi:10.18632/oncotarget.14493

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells

Sheng Tai, Lingfan Xu, Ming Xu, Ligang Zhang, Yangyang Zhang, Kaipin Zhang, Li Zhang and Chaozhao Liang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:11206-11218. https://doi.org/10.18632/oncotarget.14493

Metrics: PDF 2258 views | HTML 2826 views | ?

Abstract

Sheng Tai1,2, Lingfan Xu1,2, Ming Xu1,2, Ligang Zhang1,2, Yangyang Zhang1,2, Kaipin Zhang1,2, Li Zhang1,2, Chaozhao Liang1,2

1The Department of Urology, The First Affiliated Hospital of Anhui Medical University, China

2The Department of Urology, The Urological Institute of Anhui Medical University, China

Correspondence to:

Sheng Tai, email: [email protected]

Chaozhao Liang, email: [email protected]

Keywords: Rad001, ATO, synergism, autophagy, prostate cancer

Received: August 05, 2016 Accepted: December 27, 2016 Published: January 04, 2017

ABSTRACT

The inhibitor of PI3K-AKT-mTOR pathway, such as Rad001, has not shown therapeutic efficacy as a single agent in prostate cancer. Arsenic trioxide induces the autophagic pathway in prostate cancer cells. We identified Arsenic trioxide can synergize with Rad001 to induce cytotoxicity of prostate cancer cells. Moreover, we identified synergistic induction of autophagy and apoptosis as the underlying mechanism. This enhanced autophagic cell death is accompanied by increased Beclin1 mRNA stability as well as upregulation of ATG5-ATG12 conjugate, Beclin1, and LC3-2. Rad001 and ATO also can synergistically inhibit tumors in prostate cancer xenograft animal model. These results identify and validate a novel mechanism to enhance and expand the existing targeted therapeutic agent to treat prostate cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14493

Publication Alerts

Research Papers:

Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells

Abstract